应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
MPLT MapLight Therapeutics, Inc.
已收盘 06-24 16:00:00 EDT
30.65
+2.01
+7.02%
盘后
30.60
-0.05
-0.16%
19:04 EDT
最高
30.74
最低
28.18
成交量
38.63万
今开
28.61
昨收
28.64
日振幅
8.94%
总市值
13.90亿
流通市值
3.36亿
总股本
4,535万
成交额
1,160万
换手率
3.52%
流通股本
1,098万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
MapLight Therapeutics公司Ml-004在二期IRIS试验中总体耐受性良好,未出现严重或重度不良事件
美股速递 · 06-22 19:04
MapLight Therapeutics公司Ml-004在二期IRIS试验中总体耐受性良好,未出现严重或重度不良事件
MapLight Therapeutics, Inc.声明:Setia离职无权获得任何遣散费
美股速递 · 06-19
MapLight Therapeutics, Inc.声明:Setia离职无权获得任何遣散费
MapLight Therapeutics首席财务官Vishwas Setia于2026年6月18日起即刻离职 - 美国证券交易委员会文件披露
美股速递 · 06-19
MapLight Therapeutics首席财务官Vishwas Setia于2026年6月18日起即刻离职 - 美国证券交易委员会文件披露
MapLight Therapeutics宣布Zephyr二期临床试验完成入组并更新关键结果预期时间表
美股速递 · 05-01
MapLight Therapeutics宣布Zephyr二期临床试验完成入组并更新关键结果预期时间表
Maplight Therapeutics, Inc.盘中异动 股价大涨5.11%报18.50美元
市场透视 · 03-04
Maplight Therapeutics, Inc.盘中异动 股价大涨5.11%报18.50美元
Maplight Therapeutics, Inc.盘中异动 快速上涨5.06%
市场透视 · 01-28
Maplight Therapeutics, Inc.盘中异动 快速上涨5.06%
MapLight Therapeutics阿尔茨海默病精神病药物ML-007C-MA获FDA快速通道认定
美股速递 · 01-05
MapLight Therapeutics阿尔茨海默病精神病药物ML-007C-MA获FDA快速通道认定
加载更多
公司概况
公司名称:
MapLight Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
MapLight Therapeutics, Inc.于2018年11月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,专注于开发中枢神经系统疾病的治疗方法。其主要候选药物ML-007C-MA是一种用于治疗精神分裂症和阿尔茨海默病精神病的固定剂量复方毒蕈碱激动剂,目前处于2期试验阶段。该公司还在开发用于治疗自闭症谱系障碍社交沟通障碍的ML-004。
发行价格:
--
{"stockData":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":30.65,"timestamp":1782331200000,"preClose":28.64,"halted":0,"volume":386287,"hourTrading":{"tag":"盘后","latestPrice":30.6,"preClose":30.65,"latestTime":"19:04 EDT","volume":8614,"amount":264032.99,"timestamp":1782342273348,"change":-0.05,"changeRate":-0.001631,"amplitude":0.001631},"delay":0,"changeRate":0.07018156424580999,"floatShares":10976700,"shares":45345700,"eps":-4.412,"marketStatus":"已收盘","change":2.01,"latestTime":"06-24 16:00:00 EDT","open":28.61,"high":30.74,"low":28.18,"amount":11599837.045368,"amplitude":0.089385,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.412,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782374400000},"marketStatusCode":5,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":28.64,"postHourTrading":{"tag":"盘后","latestPrice":30.6,"preClose":30.65,"latestTime":"19:04 EDT","volume":8614,"amount":264032.99,"timestamp":1782342273348,"change":-0.05,"changeRate":-0.001631,"amplitude":0.001631},"volumeRatio":0.623921,"impliedVol":1.7223,"impliedVolPercentile":0.5},"requestUrl":"/m/hq/s/MPLT","defaultTab":"news","newsList":[{"id":"1130988345","title":"MapLight Therapeutics公司Ml-004在二期IRIS试验中总体耐受性良好,未出现严重或重度不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1130988345","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130988345?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:04","pubTimestamp":1782126257,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics公司宣布,其候选药物Ml-004在二期IRIS临床试验中表现出良好的安全性特征。试验数据显示,该药物总体耐受性良好,期间未报告任何严重或重度的不良事件。\n这一积极的安全数据为Ml-004的进一步开发奠定了重要基础。公司将继续推进相关临床研究,以评估该疗法在目标适应症中的有效性与长期安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135687202","title":"MapLight Therapeutics, Inc.声明:Setia离职无权获得任何遣散费","url":"https://stock-news.laohu8.com/highlight/detail?id=1135687202","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135687202?lang=zh_cn&edition=full","pubTime":"2026-06-19 05:07","pubTimestamp":1781816835,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc.发布声明称,根据相关协议条款,Setia先生因其离职行为,无权获得任何形式的遣散费用。公司强调,此举严格遵循了既定的雇佣合同与内部政策规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156015941","title":"MapLight Therapeutics首席财务官Vishwas Setia于2026年6月18日起即刻离职 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1156015941","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156015941?lang=zh_cn&edition=full","pubTime":"2026-06-19 05:03","pubTimestamp":1781816596,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会(SEC)的文件,生物制药公司MapLight Therapeutics, Inc.宣布,其首席财务官Vishwas Setia已于2026年6月18日即刻卸任。\n该文件显示,Setia的离职自2026年6月18日起立即生效。目前,公司尚未公布其首席财务官职位的继任计划。此次人事变动通过SEC的正式文件对外披露,标志着公司管理层的一次重要调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126953001","title":"MapLight Therapeutics宣布Zephyr二期临床试验完成入组并更新关键结果预期时间表","url":"https://stock-news.laohu8.com/highlight/detail?id=1126953001","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126953001?lang=zh_cn&edition=full","pubTime":"2026-05-01 19:00","pubTimestamp":1777633228,"startTime":"0","endTime":"0","summary":"生物制药公司MapLight Therapeutics近日宣布,其针对精神神经疾病的Zephyr二期临床试验已完成患者入组工作。该公司同时更新了这项研究的关键顶线结果预计公布时间。\n此次临床试验的顺利推进标志着MapLight Therapeutics在精神神经疾病治疗领域取得重要进展。公司表示将按计划推进后续数据整理与分析工作,并及时向市场披露相关研究成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617552908","title":"Maplight Therapeutics, Inc.盘中异动 股价大涨5.11%报18.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617552908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617552908?lang=zh_cn&edition=full","pubTime":"2026-03-04 03:41","pubTimestamp":1772566875,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日03时41分,Maplight Therapeutics, Inc.股票出现波动,股价急速拉升5.11%。截至发稿,该股报18.50美元/股,成交量7.8101万股,换手率0.17%,振幅7.81%。Maplight Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为1.80%。其相关个股中,Edesa Biotech, Inc.、Onconetix, Inc.、Hcw Biologics Inc.涨幅较大,Edesa Biotech, Inc.、Onconetix, Inc.、Adial Pharmaceuticals, Inc较为活跃,换手率分别为306.82%、199.87%、139.79%,振幅较大的相关个股有Edesa Biotech, Inc.、Onconetix, Inc.、Yd Bio Ltd C/Wts 28/08/2030,振幅分别为76.32%、47.82%、43.99%。Maplight Therapeutics, Inc.公司简介:malight Therapeutics是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304034115a447d7f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304034115a447d7f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","MPLT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606739773","title":"Maplight Therapeutics, Inc.盘中异动 快速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606739773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606739773?lang=zh_cn&edition=full","pubTime":"2026-01-28 00:41","pubTimestamp":1769532107,"startTime":"0","endTime":"0","summary":"北京时间2026年01月28日00时41分,Maplight Therapeutics, Inc.股票出现波动,股价快速拉升5.06%。截至发稿,该股报18.89美元/股,成交量7.608万股,换手率0.17%,振幅6.34%。Maplight Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.51%。其相关个股中,Biomx Inc.、Briacell Therapeutics Corp C/Wts 、Lisata Therapeutics, Inc.涨幅较大,Biomx Inc.、Vyome Holdings, Inc.、Genenta Science Spa较为活跃,换手率分别为2036.13%、748.47%、230.41%,振幅较大的相关个股有Biomx Inc.、Vyome Holdings, Inc.、Novabay Pharmaceuticals, Inc.,振幅分别为53.90%、39.87%、37.46%。Maplight Therapeutics, Inc.公司简介:malight Therapeutics是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128004148953e9a41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128004148953e9a41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","MPLT","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167154321","title":"MapLight Therapeutics阿尔茨海默病精神病药物ML-007C-MA获FDA快速通道认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1167154321","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167154321?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:02","pubTimestamp":1767614544,"startTime":"0","endTime":"0","summary":"生物制药公司MapLight Therapeutics宣布,其针对阿尔茨海默病精神病症状的候选药物ML-007C-MA已获得美国食品药品监督管理局(FDA)授予的快速通道资格。这一认定将加速该药物的临床开发与审评进程,为患者提供更早获得创新疗法的可能。\nML-007C-MA是一种针对特定神经机制的新型治疗药物,旨在缓解阿尔茨海默病患者常见的精神病性症状,如幻觉、妄想和激越行为。快速通道资格的获得,意味着FDA认可该药物在未满足医疗需求领域的潜在价值,并将通过更频繁的沟通、滚动审评等机制支持其研发。\n公司表示将积极推进后续临床试验,力争早日为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maplightrx.com","stockEarnings":[{"period":"1week","weight":0.0545},{"period":"1month","weight":-0.0038},{"period":"3month","weight":0.5788},{"period":"6month","weight":0.5806},{"period":"1year","weight":0.6847},{"period":"ytd","weight":0.6305}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.1169},{"period":"6month","weight":0.0626},{"period":"1year","weight":0.2223},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MapLight Therapeutics, Inc.于2018年11月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,专注于开发中枢神经系统疾病的治疗方法。其主要候选药物ML-007C-MA是一种用于治疗精神分裂症和阿尔茨海默病精神病的固定剂量复方毒蕈碱激动剂,目前处于2期试验阶段。该公司还在开发用于治疗自闭症谱系障碍社交沟通障碍的ML-004。","exchange":"NASDAQ","name":"MapLight Therapeutics, Inc.","nameEN":"MapLight Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MapLight Therapeutics, Inc.(MPLT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MapLight Therapeutics, Inc.(MPLT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MapLight Therapeutics, Inc.,MPLT,MapLight Therapeutics, Inc.股票,MapLight Therapeutics, Inc.股票老虎,MapLight Therapeutics, Inc.股票老虎国际,MapLight Therapeutics, Inc.行情,MapLight Therapeutics, Inc.股票行情,MapLight Therapeutics, Inc.股价,MapLight Therapeutics, Inc.股市,MapLight Therapeutics, Inc.股票价格,MapLight Therapeutics, Inc.股票交易,MapLight Therapeutics, Inc.股票购买,MapLight Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MapLight Therapeutics, Inc.(MPLT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MapLight Therapeutics, Inc.(MPLT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}